Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The Liver Imaging Reporting and Data System (LI-RADS) is a comprehensive system that uses standardized terminology, technique, interpretation, and reporting of imaging studies for hepatocellular carcinoma surveillance, diagnosis, and locoregional treatment response assessment. Since its initial release in 2011, LI-RADS has evolved and expanded in scope. In this article, we discuss recent updates intended to address clinical needs and mitigate current challenges.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11604338 | PMC |
| http://dx.doi.org/10.3348/kjr.2024.0161 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Value of enhancing capsule for diagnosing hepatocellular carcinoma on MRI: implications for simplifying LI-RADS.
Eur Radiol
August 2025
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Objective: We evaluated the value of EC as a major feature for hepatocellular carcinoma (HCC) and its implications on simplifying LI-RADS v2018: by either excluding EC (LI-RADS[EC(-)]), or treating EC as equivalent to other major features (LI-RADS[EC(+)]).
Materials And Methods: This retrospective study included patients who underwent preoperative MRI within 1 month of surgery. Two radiologists independently assigned LI-RADS categories, with consensus resolution.
Prognostic and predictive imaging markers of hepatocellular carcinoma: a pictorial essay.
Insights Imaging
August 2025
Department of Radiology, Radiation Oncology, and Nuclear Medicine, Université de Montréal, Montréal, Québec, Canada.
Hepatocellular carcinoma (HCC) encompasses a wide array of histopathologic and genetic features that can be broadly categorized as proliferative or non-proliferative HCC to reflect tumor aggressiveness. However, accurately characterizing tumor behavior remains challenging due to the biologic heterogeneity of HCC and limited access to tissue samples. Currently, imaging is used for the diagnosis of HCC using the Liver Imaging Reporting and Data System (LI-RADS) without histologic confirmation in most cases.
View Article and Find Full Text PDFLR-M for CT/MRI on LI-RADS v2018: a review of imaging criteria, performance, challenges and future directions from an end-user perspective.
Abdom Radiol (NY)
August 2025
University of Alberta, Edmonton, Canada.
LR-M is a category within the Liver Imaging Reporting and Data System (LI-RADS) that refers to liver observations that are probably or definitely malignant but are not specific to hepatocellular carcinoma (HCC). It includes etiologies such as atypical HCC, intrahepatic cholangiocarcinoma, combined hepatocellular cholangiocarcinoma and metastases. The primary aim of LR-M is to ensure a high sensitivity for detecting all hepatic malignancies while preserving a high specificity for HCC in LR-5.
View Article and Find Full Text PDFImaging-based diagnosis of hepatocellular carcinoma: Liver Imaging Reporting and Data System and beyond.
Br J Radiol
September 2025
Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States.
Hepatocellular carcinoma (HCC) is currently the third leading cause of cancer-related death globally. It is unique among other cancers in the sense that imaging-based diagnosis is accepted as a definite diagnosis among at-risk patients by all major guidelines. The classic imaging finding of HCC on multiphasic contrast-enhanced CT and MRI is hyperenhancement during the arterial phase with hypoenhancement ("washout") and enhancing capsule in the portal venous and/or delayed phases.
View Article and Find Full Text PDFCT and MRI features of Catenin Beta 1-mutated hepatocellular carcinoma in a Western cohort.
Abdom Radiol (NY)
June 2025
Memorial Sloan Kettering Cancer Center, New York, USA.
Objectives: Various mutations in hepatocellular carcinoma (HCC) carry prognostic implications. The objective of this study is to assess CT and MRI imaging features associated with Catenin Beta-1 (CTNNB1) mutation in HCC.
Methods: This retrospective, IRB- approved multi-reader, single-center study included treatment-naive, pathologic-proven HCC that underwent contrast-enhanced CT, MRI or both, with subsequent targeted tumor sequencing test.